Contact

 

Prof. Dr. med. Peter Schirmacher

Please contact:
Dr. Katrin Woll
E-mail: katrin.woll@med.uni-heidelberg.de

 

 

Pathology is...

 

disease-oriented research for tomorrows medicine and up-to-date tissue diagnostics for our patients

Institute of Pathology

 

Our group/department has:

  • Top ranked pathology center with 20 independently third party funded research groups covering all areas of cancer research (publication scores 2013: XX peer reviewed research publications; cumulative IF: >950 ; average IF: 5,7)

  • SFB/TRR77 Liver Cancer – From Molecular Pathogenesis to Targeted Therapies (Coordinator: P. Schirmacher) (since 2010) with 24 projects and 6 associated projects and initiation of the Liver Cancer Center Heidelberg (LCCH); participation of the Institute in more than 20 research consortia

  • Biomarker Development Unit (Prof. W. Weichert) providing comprehensive biomarker development from preclinical analyses over trial associated molecular diagnostics to diagnostic roll out (3 third party funded)

  • Diagnostic Trial Center (founded in 1/2012) with allocated diagnostic testing in 7 national and international phase I-III cancer trials (focus predictive diagnostics) including world wide testing for phase I/II trials (eg. LDK, BGJ)

  • BioMaterialBank Heidelberg (BMBH; speaker: P. Schirmacher) as the comprehensive biobank structure in Heidelberg aiming at harmonized and coordinated biobanking (since 2011; third party funding for Biobanking (BMBF, DFG, DKH))

2010 – 2013

  • Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, Bussemaker HJ, Singer RH, Schirmacher P, Prives C. Nuclear Pore Component Nup98 Is a Potential Tumor Suppressor and Regulates Posttranscriptional Expression of Select p53 Target Genes. Mol Cell. 2012;48(5):799-810.

  • Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H, Weichert W. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;1;30(13):1438-46.

  • Kloor M, Voigt AY, Schackert HK, Schirmacher P, von Knebel Doeberitz M,  Blaeker H. Analysis of EPCAM protein expression in diagnostics of Lynch syndrome J Clin Oncol. 2011;29(2):223-7.

  • Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, Sticht C, Tomasi ML, Delogu S, Evert M, Fan B, Ribback S,Jiang L, Brozzetti S, Bergmann F, Dombrowski F, Schirmacher P, Calvisi DF, Breuhahn K. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 2013;144(7):1530-1542.e12.

  • Goeppert B, Konermann C, Schmidt CR, Bogatyrova O, Geiselhart L, Ernst C, Gu L, Becker N, Zucknick M, Mehrabi A, Hafezi M, Klauschen F, Stenzinger A, Warth A, Breuhahn K, Renner M, Weichert W, Schirmacher P, Plass C, Weichenhan D. Global alterations of DNA methylation in cholangiocarcinoma targets the Wnt signaling pathway. Hepatology. 2013 Sep 3. doi: 10.1002/hep.26721.

  • BMBF - BioMaterialBankHeidelberg BMBH; 2011-2016; (Coordinator P. Schirmacher)

  • BMBF – Virtual Liver - Project A2.4 “Linking signalling pathways regulating liver regeneration and organsize Control”and Project B1.2 “Reciprocal effect of cell-cell communication on information processing in macrophages and hepatocytes”(Subproject coordinator P. Schirmacher); 2010-2015